Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
‘Ukrainian housewives’ and Skyranger delays – German defense poster child Rheinmetall is in hot water - 2Cannabis reclassification could 'open the floodgates' for research, scientists say
- 36 Popular Ladies' Aromas On the planet
- 4Two IDF officers, civilian face indictment in alleged Gaza aid-truck smuggling scheme
- 59 Under-The-Radar Malaysian Islands To Consider Instead Of Thailand Or Indonesia
- Israel has clear objectives south of Litani River, but will face difficult choices further north
- 7 Extraordinary Efficiency Applications for Experts
- April's full moon decides the date of Easter — here's how it works
- Vote in favor of your Number one Kind of Shades
- 6 Vehicle Rental Administrations: Pick Your Ideal Ride
- My skin feels drier, my lips thinner and my makeup heavier. How do I adjust my routine for aging skin?
- 'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
- NASA's Voyager 1 set to achieve historic distance from Earth
- The Best Internet based Courses for Expertise Improvement
